Cardiac microvascular barrier function mediates the protection of Tongxinluo against myocardial ischemia/reperfusion injury

PLoS One. 2015 Mar 17;10(3):e0119846. doi: 10.1371/journal.pone.0119846. eCollection 2015.

Abstract

Objective: Tongxinluo (TXL) has been shown to decrease myocardial necrosis after ischemia/reperfusion (I/R) by simulating ischemia preconditioning (IPC). However, the core mechanism of TXL remains unclear. This study was designed to investigate the key targets of TXL against I/R injury (IRI) among the cardiac structure-function network.

Materials and methods: To evaluate the severity of lethal IRI, a mathematical model was established according to the relationship between myocardial no-reflow size and necrosis size. A total of 168 mini-swine were employed in myocardial I/R experiment. IRI severity among different interventions was compared and IPC and CCB groups were identified as the mildest and severest groups, respectively. Principal component analysis was applied to further determine 9 key targets of IPC in cardioprotection. Then, the key targets of TXL in cardioprotection were confirmed.

Results: Necrosis size and no-reflow size fit well with the Sigmoid Emax model. Necrosis reduction space (NRS) positively correlates with I/R injury severity and necrosis size (R2=0.92, R2=0.57, P<0.01, respectively). Functional and structural indices correlate positively with NRS (R2=0.64, R2=0.62, P<0.01, respectively). TXL recovers SUR2, iNOS activity, eNOS activity, VE-cadherin, β-catenin, γ-catenin and P-selectin with a trend toward the sham group. Moreover, TXL increases PKA activity and eNOS expression with a trend away from the sham group. Among the above nine indices, eNOS activity, eNOS, VE-cadherin, β-catenin and γ-catenin expression were significantly up-regulated by TXL compared with IPC (P>0.05) or CCB (P<0.05) and these five microvascular barrier-related indices may be the key targets of TXL in minimizing IRI.

Conclusions: Our study underlines the lethal IRI as one of the causes of myocardial necrosis. Pretreatment with TXL ameliorates myocardial IRI through promoting cardiac microvascular endothelial barrier function by simulating IPC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cardiotonic Agents / therapeutic use*
  • Drugs, Chinese Herbal / therapeutic use*
  • Female
  • Heart / drug effects*
  • Hemodynamics / drug effects
  • Ischemic Preconditioning
  • Male
  • Models, Theoretical
  • Myocardium / pathology*
  • No-Reflow Phenomenon
  • Principal Component Analysis
  • Reperfusion Injury / drug therapy*
  • Reperfusion Injury / pathology
  • Swine

Substances

  • Cardiotonic Agents
  • Drugs, Chinese Herbal
  • tongxinluo

Grants and funding

This study was supported by National Basic Research Program (973 Program) of China (No. 2012CB518602; No. 2005CB523303, http://www.973.gov.cn/AreaAppl.aspx; KQ, XL, JZ, SY, FH, HZ, YC, SK, HC, LD, CJ, YY), National Natural Science Foundation of China (No. 81370223; No. 30770858; No. 30572439; No. 902090038, http://www.nsfc.gov.cn; KQ, XL, JZ, SY, FH, HZ, YC, SK, HC, LD, CJ, YY), Beijing Natural Science Foundation (No. 7042044, http://www.bjnsf.org; JZ, SY, FH, CJ, YY), Capital Medical Development Scientific Research Fund (No. 2002-3072, http://www.bjhbkj.com; JZ, SY, FH, CJ, YY) and Postgraduates’ Innovative Foundation of Peking Union Medical College, China (2013-1002-39; http://graduate.pumc.edu.cn/peiyang/view/86.aspx; KQ). All funders has no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.